Asymchem Laboratories (06821) announced its interim results, with a net profit attributable to shareholders of 520 million yuan, a year-on-year decrease of 15.71%.

Asymchem Laboratories (06821) announced its interim results for the six months ended June 30, 2026. The group reported revenue of 3.607 billion yuan (RMB, same below), an increase of 13.13% year-on-year; net profit attributable to shareholders of the parent company was 520 million yuan, a decrease of 15.71% year-on-year; basic earnings per share stood at 1.45 yuan. The gross profit margin for the first half of 2026 was 41.99%, a decline of 1.27 percentage points compared to the same period last year. Relying on its competitive advantages accumulated in small molecule CDMO, the company is accelerating the development of its talent team and capabilities to promote the rapid growth of strategic emerging businesses such as chemical macromolecule CDMO, biological macromolecule CDMO, formulation, clinical research services, and synthetic biology and new technology output. During the reporting period, strategic emerging businesses achieved revenue of 1.304 billion yuan, a year-on-year increase of 72.49%. The revenue from chemical macromolecule (including peptide, oligonucleotide, toxin conjugate, and liposome business) CDMO was 736 million yuan in the first half of 2026, a year-on-year increase of 94.14%. The formulation CDMO business segment reported revenue of 178 million yuan in the first half of 2026, a year-on-year increase of 50.93%. The clinical research services segment achieved revenue of 143 million yuan, an increase of 2.73% year-on-year. The biological macromolecule CDMO business segment had revenue of 200 million yuan in the first half of 2026, a year-on-year increase of 122.82%.